Pressure BioSciences (OTCQB: PBIO) was recently granted another patent to add to its intellectual property (“IP”) portfolio regarding its development of an automated “hands-free” sample handling for the next generation of the company’s high-pressure sample preparation platform systems. A recent article discussing the company’s technology reads, “The global sample preparation market is projected to reach $8.2 billion by 2024, according to a report by TransparencyMarketResearch (http://ibn.fm/wCaOd). Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument system, which can be used to exquisitely control the sample preparation process. Based on the company’s patented and enabling pressure cycling technology (PCT) platform, over 300 Barocycler systems have been installed in approximately 200 academic, government, pharmaceutical and biotech research laboratories worldwide. These laboratories use the PCT instrument system for multiple applications, including the preparation of samples for biomarker and target discovery, soil & plant biology, anti-bioterror and forensics studies. There are over 100 independent scientific publications highlighting the advantages of the PCT system in such studies, many from worldwide key opinion leaders.
To view the full article, visit http://ibn.fm/V2hNj
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
